Novel Two-Prong Biologic Shows Promise in Asthma
(MedPage Today) -- The unique dual inflammation blockade of investigational lunsekimig showed promise for moderate-to-severe asthma in the phase II AIRCULES study. Targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, lunsekimig...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.